To systematically compare the burden of gout and its attributable risk factors between China and EU member states from 1990 to 2023, focusing on specific intervals of data from GBD 2023.
Key Findings:
Gout prevalence and incidence are increasing globally, with significant regional variations, particularly in Asia, highlighting the need for targeted public health interventions.
China shows a marked increase in gout prevalence, with many patients not receiving timely interventions, indicating a gap in healthcare delivery.
Gaps in treatment adherence and management of comorbidities hinder improvements in gout outcomes, necessitating a review of current treatment protocols.
Interpretation:
The study highlights the rising burden of gout in China compared to the EU, emphasizing the need for region-specific prevention and control strategies, such as public awareness campaigns and healthcare access improvements.
Limitations:
Potential differences in clinical diagnostic practices between China and EU countries may not be fully captured, which could skew prevalence estimates.
The analysis is based on publicly available data, which may have inherent limitations, such as reporting biases or incomplete data.
Conclusion:
The findings underscore the importance of addressing the growing gout burden in China and the EU, advocating for improved management strategies, such as enhanced patient education and further research into effective treatment options.
